[Form 4] CRYO CELL INTERNATIONAL INC Insider Trading Activity

Rhea-AI Filing Summary

Cryo-Cell International (CCEL) insider David I. Portnoy (Director, 10% Owner, Chairman, Co-CEO) reported open-market purchases of common stock. He acquired 1,026 shares at $4.18 on 11/10/2025, 2,474 shares at a weighted average price of $4.13 on 11/11/2025, and 2,040 shares at a weighted average price of $4.12 on 11/12/2025. Following these trades, his direct beneficial ownership stands at 842,550 shares.

He also reports derivative holdings, including 280,000 stock options at $12.27 expiring 12/22/2028, which vest immediately if the stock reaches $25 during the seven-year term.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PORTNOY DAVID

(Last) (First) (Middle)

700 BROOKER CREEK BLVD

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		A		1,026	A	$4.18	838,036	D
Common Stock	11/11/2025		A		2,474	A	$4.13(1)	840,510	D
Common Stock	11/12/2025		A		2,040	A	$4.12(2)	842,550	D
Common Stock								161,833	I	By Corporation(3)
Common Stock								164,182	I	By 401K
Common Stock								268,878	I	By IRA
Common Stock								107,403	I	By Spouse
Common Stock								11,537	I	As Custodian for son
Common Stock								11,398	I	As Custodian for son
Common Stock								10,939	I	As Custodian for son
Common Stock								57,306	I	By Corporation(4)
Common Stock								59,027	I	By LLC(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.53							08/30/2019	08/30/2029	Common stock	26,243		26,243	D
Stock Option	$7.28							12/20/2019	12/20/2029	Common Stock	23,636		23,636	D
Stock Option	$12.27							12/22/2021(6)	12/22/2028	Common Stock	280,000		280,000	D
Stock Option	$4.77							01/03/2023(7)	01/03/2028	Common Stock	50,000		50,000	D
Stock Option	$4.3							12/23/2022	12/23/2027	Common Stock	50,000		50,000	D
Stock Option	$6.47							12/22/2023(8)	12/22/2028	Common Stock	50,000		50,000	D
Stock Option	$8.08							01/21/2025(9)	01/21/2030	Common Stock	50,000		50,000	D

Explanation of Responses:

1. The price reported is a weighted average price of $4.13. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

2. The price reported is a weighted average price of $4.12. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

3. Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary.

4. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.

5. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.

6. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.

7. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.

8. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

9. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.

	/s/ David Portnoy	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CCEL's David I. Portnoy report?

He bought 1,026 shares at $4.18 (11/10/2025), 2,474 at a weighted avg $4.13 (11/11/2025), and 2,040 at a weighted avg $4.12 (11/12/2025).

What is David I. Portnoy’s direct beneficial ownership in CCEL after these trades?

Direct holdings are 842,550 shares following the reported transactions.

What roles does David I. Portnoy hold at Cryo-Cell (CCEL)?

He is a Director, 10% Owner, and serves as Chairman and Co-CEO.

Were the reported prices for 11/11 and 11/12 weighted averages?

Yes. The filing states weighted average prices of $4.13 (11/11/2025) and $4.12 (11/12/2025).

What notable stock options does Portnoy hold?

He holds 280,000 options at $12.27 expiring 12/22/2028; they vest immediately if the stock reaches $25 during the seven-year term.

Does the filing list indirect holdings?

Yes. It lists multiple indirect positions, including shares held by entities and family-related accounts, with amounts shown in the tables.